QURE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
uniQure NV (QURE) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown some financial improvements and potential for growth, the negative sentiment from lawsuits, FDA approval issues, and lack of strong technical or proprietary trading signals suggest caution. Holding off until more clarity on the legal and regulatory issues is advisable.
The MACD is negatively expanding (-0.0622), RSI is neutral at 33.828, and moving averages are converging, indicating no clear trend. The stock is near its S1 support level of 22.861, with resistance at 25.229. Overall, the technical indicators do not suggest a strong buy signal.
Revenue increased by 61.83% YoY in Q3 2025, and gross margin improved by 61.22% YoY. Analysts have a generally positive long-term view of the biotech sector, with expectations for mergers and acquisitions and strong fundamentals.
Multiple class action lawsuits alleging undisclosed FDA approval issues have created significant negative sentiment. The FDA's concerns about AMT-130 data may delay key product launches. Insider and hedge fund activity is neutral, indicating no strong support from key stakeholders.
In Q3 2025, revenue increased by 61.83% YoY to $3.7 million, net income improved by 81.46% YoY but remains negative at -$80.53 million, and EPS improved by 51.65% YoY to -1.38. Gross margin increased to 89.25%. While there is growth, the company is still unprofitable.
Barclays initiated coverage with an Equal Weight rating and a $31 price target, reflecting a neutral stance. Stifel and Mizuho lowered their price targets to $40 and $33, respectively, citing delays and reduced probability of success for key products. Analysts remain cautiously optimistic about the biotech sector but are less confident in QURE specifically.
